Andrew Perry - Jan 3, 2024 Form 4 Insider Report for G1 Therapeutics, Inc. (GTHX)

Role: Chief Commercial Officer
Signature: /s / Monica Roberts Thomas, attorney-in-fact
Stock symbol: GTHX
Transactions as of: Jan 3, 2024
Transactions value $: -$7,526
Form type: 4
Date filed: 1/8/2024, 06:03 AM
Previous filing: Jul 7, 2023
Next filing: May 15, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GTHX	Common Stock	Award	$0	+33.6K	+60.01%	$0.00	89.5K	Jan 3, 2024	Direct	F1, F2, F3
transaction	GTHX	Common Stock	Sale	-$1.18K	-379	-0.42%	$3.12	89.1K	Jan 3, 2024	Direct	F4, F5, F6
transaction	GTHX	Common Stock	Sale	-$6.34K	-2.03K	-2.28%	$3.12	87.1K	Jan 3, 2024	Direct	F4, F5, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GTHX	Stock Options (Right to Buy)	Award	$0	+67.1K		$0.00	67.1K	Jan 3, 2024	Common Stock	67.1K	$2.97	Direct	F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2025 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F2	Each RSU represents a contingent right to receive one share of Issuer common stock.
F3	Represents (i) 1,095 shares of common stock; (ii) 3,750 RSUs from award granted on January 3, 2022; (iii) 16,100 RSUs from award granted on January 3, 2023; (iv) 35,000 RSUs from award granted on May 10, 2023; and (v) 33,570 RSUs from award granted on January 3, 2024.
F4	The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a sell-to-cover transaction and do not represent discretionary transactions by the Reporting Person.
F5	The price represents the weighted average price with a low of $3.08 and a high of $3.16. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6	Represents (i) 1,466 shares of common stock; (ii) 3,000 RSUs from award granted on January 3, 2022; (iii) 16,100 RSUs from award granted on January 3, 2023; (iv) 35,000 RSUs from award granted on May 10, 2023; and (v) 33,570 RSUs from award granted on January 3, 2024.
F7	Represents (i) 3,457 shares of common stock; (ii) 3,000 RSUs from award granted on January 3, 2022; (iii) 12,075 RSUs from award granted on January 3, 2023; (iv) 35,000 RSUs from award granted on May 10, 2023; and (v) 33,570 RSUs from award granted on January 3, 2024.
F8	The shares underlying this option vest as to 25% of the shares on January 3, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.